Abstract
Introduction
The recent publication of a national guideline and quality standards in Canada have provided clinicians with new, evidence-based recommendations on safe, appropriate opioid use. We sought to characterize how well opioid initiation practices aligned with these recommendations before and following their release.
Methods
We conducted a population-based study among people initiating opioids prior to the release of national guidelines (April 2015—March 2016; fiscal year [FY] 2015) and in the most recent year available (January—December 2019) in Ontario, Canada. We used linked administrative claims data to ascertain the apparent indication for opioid therapy, and characterized the initial daily dose (milligrams morphine or equivalent; MME) and prescription duration for each indication.
Results
In FY2015, 653,885 individuals commenced opioids, compared to 571,652 in 2019. Over time, there were small overall reductions in the prevalence of initial daily doses exceeding 50MME (23.9% vs. 20.1%) and durations exceeding 7 days (17.4% vs. 14.8%); but the magnitude of the reductions varied widely by indication. The prevalence of high dose (>50MME) initial prescriptions reduced significantly across all indications, with the exception of dentist-prescribed opioids (13.6% vs. 12.1% above 50MME). In contrast, there was little change in initial durations exceeding 7 days across most indications, with the exception of some surgical indications (e.g. common excision; 9.3% vs. 6.2%) and among those in palliative care (35.2% vs. 29.2%).
Conclusion
Despite some modest reductions in initiation of high dose and long duration prescription opioids between 2015 and 2019, clinical practice is highly variable, with opioid prescribing practices influenced by clinical indication. These findings may help identify medical specialties well-suited to targeted interventions to promote safer opioid prescribing.
Funder
Canadian Institutes of Health Research
Publisher
Public Library of Science (PLoS)
Reference29 articles.
1. Government of Canada. Opioid and Stimulant-Related Harm in Canada 2020 https://health-infobase.canada.ca/substance-related-harms/opioids-stimulants/graphs?index=791.
2. U.S. Centers for Disease Control and Prevention. Opioid Data Analysis and Resources 2021 https://www.cdc.gov/drugoverdose/data/analysis.html.
3. Public Health Ontario. Interactive Opioid Tool: Opioid-related morbidity and mortality in Ontario: Public Health Ontario; 2019 https://www.publichealthontario.ca/Data%20and%20Analysis/Substance%20Use/Interactive%20Opioid%20Tool.
4. Understanding the Implications of a Shifting Opioid Landscape in Ontario;T Gomes;Healthc Q,2019
5. U.S. Centers for Disease Control and Prevention. Understanding the Epidemic 2020 https://www.cdc.gov/drugoverdose/epidemic/index.html.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献